Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elevate-HF
2026-526304-79-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 35
01
Overview
Phase 3, randomised, double-blind trial in heart failure with preserved ejection fraction (HFpEF) and heart failure with mid-range ejection fraction (HFmrEF) comparing Elecoglipron + dapagliflozin with Placebo + dapagliflozin (2 arms). Primary endpoint: Time to first occurrence of cardiovascular death, hospitalization for heart failure, or urgent heart failure visit. Planned start Aug 2026; status: authorised.
02
Drugs
elecoglipron
03
Conditions
heart failure with preserved ejection fraction (HFpEF)heart failure with mid-range ejection fraction (HFmrEF)
Beyond the preview
Go deeper on 2026-526304-79-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526304-79-00.